Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Consumer healthcare firms are perfectly placed to lead the charge in fighting climate change while benefitting from the transition to a greener, healthier world. However, taking advantage of the green opportunity means putting environmental, social and governance (ESG) at the center of how OTC companies measure and reward success and treating the health of people and planet as a single, related issue, argues Bayer Consumer Health's sustainability guru Daniella Foster.
Where the European Commission and Member States land in their final deliberations on the proposed microplastic ban could reveal a lot about industry costs deemed acceptable and the level of science considered necessary to regulate cosmetics and other markets in pursuance of Green Deal objectives.
AESGP Regulatory Conference: EU Pharma Strategy, Med Devices Regs, European Green Deal And GCSF Sustainability Charter Launch
HBW Insight reports on a packed agenda at the AESGP's Regulatory Conference on 25 November. Panels discuss the implications of raft of legislative changes for the European self-care industry, including the incoming EU Pharmaceutical Strategy, the new Medical Devices Regulations, and the inter-related European Green Deal, Farm to Fork and Chemicals Strategies. The conference also saw the launch of the GSCF's Charter for Environmentally Sustainable Self-Care.
The Global Self-Care Federation (GSCF) launches today its “Charter for Environmentally Sustainable Self-Care,” which it describes as the world’s “first commitment from the consumer health industry to drive sustainable self-care.”
A growing number of cosmetics companies are throwing out plastic packaging once and for all. Estee Lauder Companies and e.l.f. Cosmetics announce the latest in their transition to sustainable paper packaging, while Shiseido highlights its ocean conservation work.
In this episode, HBW Insight’s US and EU editors analyse Q3 OTC business trends, including why the biggest pharmaceutical companies in the world are spinning out their consumer health businesses to create new standalone firms and what's causing the supply chain troubles that are driving up OTC product prices.
The Environmental Protection Agency does not have the jurisdiction to grant William D. Bush’s request, even if the petitioner had specified the “chemical mixtures” he wants banned or provided the level of data required to initiate proceedings under the Toxic Substances Control Act.
GSK Consumer Healthcare is giving young people and their parents in the UK the tools to help them avoid air pollution.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.